Press Release

Carl Zeiss Meditec AG reports further growth and defines expectations for fiscal year 2018/19

12 April 2019

Jena/Germany | Carl Zeiss Meditec AG

Carl Zeiss Meditec (ISIN: DE0005313704) has grown revenues to around €667m in the first six months of fiscal year 2018/19, based on preliminary data. This corresponds to a growth rate of approx. 9% against the previous year’s value of €613.7m. Adjusted for currency effects, the growth rate was around 7%.

Carl Zeiss Meditec now further defines its expectations for the full year 2018/19: Revenue is expected to reach between €1,350m and €1,420m (previous year: €1,280.9m).

Earnings before interest and taxes (EBIT) are expected to rise significantly in the first half of 2018/19 to a level of around €110m (previous year: €88.2m). EBIT margin (EBIT as a % of revenue) will amount to around 16.5% in the first half of 2018/19 (prior year: 14.4%). The increase was supported by a positive trend in product mix with a high share of recurring revenue, in particular.

In light of these developments, Carl Zeiss Meditec raises the expectation for full year EBIT margin. EBIT margin is now expected to reach a corridor of 15.0% - 17.5% (previously: 14.0% - 16.0%). EBIT margin had amounted to 15.4% in the previous year 2017/18.

The six months 2018/19 financial report will be published on May 6, 2019.

Press & Investor Relations Contact Sebastian Frericks

Head of Group Finance & Investor Relations
Carl Zeiss Meditec AG
Phone: +49 3641 220 116
investors.med@zeiss.com

Brief profile

Carl Zeiss Meditec AG (ISIN: DE0005313704), which is listed on the MDAX and TecDAX of the German stock exchange, is one of the world's leading medical technology companies. The Company supplies innovative technologies and application-oriented solutions designed to help doctors improve the quality of life of their patients. The Company offers complete solutions, including implants and consumables, to diagnose and treat eye diseases. The Company creates innovative visualization solutions in the field of microsurgery. With 5,730 employees worldwide, the Group generated revenue of €2,066.1m in fiscal year 2023/24 (to 30 September).

The Group’s head office is located in Jena, Germany, and it has subsidiaries in Germany and abroad; more than 50 percent of its employees are based in the USA, Japan, Spain and France. The Center for Application and Research (CARIn) in Bangalore, India and the Carl Zeiss Innovations Center for Research and Development in Shanghai, China, strengthen the Company's presence in these rapidly developing economies. Around 39 percent of Carl Zeiss Meditec AG’s shares are in free float. Approx. 59 percent are held by Carl Zeiss AG, one of the world’s leading groups in the optical and optoelectronic industries.

For more information visit our website at www.zeiss.com/med

Further articles

11 December 2024

Carl Zeiss Meditec closes fiscal year 2023/24 with slight decline in revenue – adjusted EBIT forecast achieved

12 September 2024

ZEISS Redefines Disease Management and Treatment within the ZEISS Retina Workflow

Press portal

Get all press releases of the Carl Zeiss Meditec AG here:

Share this article